Inhibitory effect of α1D/1A antagonist 2-(1H-indol-3-yl)-N-[3-(4-(2-methoxyphenyl) piperazinyl) propyl] acetamide on estrogen/androgen-induced rat benign prostatic hyperplasia model in vivo
Inhibitory effect of α1D/1A antagonist 2-(1H-indol-3-yl)-N-[3-(4-(2-methoxyphenyl) piperazinyl) propyl] acetamide on estrogen/androgen-induced rat benign prostatic hyperplasia model in vivo
复制标题
α(1D/1A)拮抗剂2-(1H-吲哚-3-基)-N-[3-(4-(2-甲氧基苯基)哌嗪基)丙基]乙酰胺对雌/雄激素诱导的大鼠良性前列腺增生的抑制作用
DOI:
10.1016/j.ejphar.2019.172817
复制
发表时间:
2020-03-05
影响因子:
5
通讯作者:
Huang, Jun-jun
中科院分区:
文献类型:
--
作者:
Liu, Qi-meng;Xiao, Qing;Huang, Jun-jun
Benign prostatic hyperplasia (BPH) is a common disorder of the urinary system in aging men. 2-(1H-indol-3-yl)-N[3-(4-(2 methoxyphenyl) piperazinyl) propyl] acetamide (HJZ-3), which is derived from naftopidil, exhibited 97.7- and 64.6-fold greater inhibitory effects for a m adrenoceptor than for alpha(1B)- and alpha(1A)-adrenoceptors in vitro, respectively. To investigate the therapeutic potential for treating BPH, we evaluated the pharmacological activity of HJZ-3. Specifically, we evaluated through estrogen/androgen-induced rat benign prostatic hyperplasia model in vivo. HJZ-3 effectively prevented the progression of rat prostatic hyperplasia by suppressing the increase in prostate index and reducing the quantitative analysis of the relative acinus volume, relative stroma, epithelial volume and epithelial thickness and expression of proliferating cell nuclear antigen and a-smooth muscle actin. HJZ-3 decreased alpha(1A)- and alpha(1D)-adrenoceptor protein expressions in prostate tissue. HJZ-3 is a good alternative for alpha(1A)- and alpha(1D)-adrenoceptor blocker. It may relax smooth muscle tone and relieve symptoms of BPH.